Saltikva for Metastatic Pancreatic Cancer (NCT04589234)
A Phase 2 Study of Saltikva (Attenuated Salmonella Typhimurium Containing the Human Gene for Interleukin-2) in Patients With Metastatic Pancreatic Cancer
🩺 Plain-English Summary (8th-Grade Level)
Objectives: Assess the efficacy of multiple dose oral administration of Saltikva, an attenuated strain of Salmonella Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on standard chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane and Saltikva). Study Rationale: The addition of Saltikva to the standard of care regimen for Stage IV metastatic pancreatic cancer will significantly prolong the overall survival and prolong the time to disease progression. Patient Population: unresectable, metastatic pancreatic cancer patients 18 years of age or older
Who can join: Review the eligibility criteria below.
Location: Segal Cancer Centre/ Mortimer B. Davis-Jewish General Hosptial — Montreal, Quebec
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Segal Cancer Centre/ Mortimer B. Davis-Jewish General Hosptial — Montreal, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Pancreatic Cancer
- Proglumide and Chemotherapy for Metastatic Pancreatic Cancer — Washington D.C., District of Columbia
- Redefining FOLFIORINOX in Older Pancreatic Cancer Patients — Philadelphia, Pennsylvania
- Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy — New Hyde Park, New York
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. — Baltimore, Maryland
- Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer — Dallas, Texas
Explore by condition: All Metastatic Pancreatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.